# Teo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/teo

- Industry: Software
- Headquarters: Bordeaux, France
- Website: www.teo-med.fr/
- Total disclosed funding: $3.3M
- Latest round: Series A (Apr 16, 2021)
- Investors on record: 1

## About

Based in Bordeaux, France, Teleophtalmo, SAS doing business as Teo operates in the healthcare sector, focusing on ophthalmology services, providing support for opening and managing the practice. The company was founded by Antoine Peyssonnel, who has a history of establishing healthcare solutions. Teo raised an amount of venture funding from investor Creadev.

The company specializes in the provision of ophthalmology services through a network of over 50 operational clinics across France, primarily addressing the challenges posed by medical deserts where access to healthcare is limited. Their core offerings include a telemedicine platform that facilitates patient consultations, enabling patients to secure appointments in an average of 16 days. The company has developed a software solution that centralizes the management of patient appointments, financial transactions, and overall clinic operations, streamlining workflows for both ophthalmologists and orthoptists. Additionally, it provides real estate, administrative and logistics management, and HR management services.

Teo's revenue model is predominantly structured around service fees generated from the operational management of ophthalmology clinics and telemedicine consultations. Revenue is derived from B2B partnerships with ophthalmologists and healthcare institutions, who benefit from the company's administrative, logistical, and technical support services. Transactions typically involve fixed monthly fees for the use of the telemedicine platform, as well as a percentage of the consultation fees charged to patients.

Teo has raised an amount of venture funding from investor Creadev, which will be utilized to enhance its telemedicine platform and expand service offerings. The company plans to introduce new features aimed at improving patient engagement and operational efficiency in the next year. Furthermore, Teo is targeting expansion into additional regions of France that are currently underserved in ophthalmology by the end of 2024, leveraging recent investments to facilitate this growth.

## Funding rounds

- Series A, Apr 16, 2021, $3.3M — Creadev

## Investors

- Creadev — Series A